Successful outcome of psoriasis in a laryngeal cancer patient treated with ixekizumab, a possible beneficial treatment for both pathologies

Saura, Saray Porcar; Casimiro, Lucía Martínez; García‐Vázquez, Alejandro; Benavent, Martí Pons; Guillén-Climent, Santiago; Villaescusa, E. Montesinos

doi:10.5070/d327654071

Cited by 6 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During a comparable follow-up duration, there were no statistically significant variances found in terms of disease relapses (p-value = 0.66). Furthermore, in the literature, there are case reports of patients with a history or recent diagnosis of neoplasia who were effectively and safely treated with biologic drugs [71][72][73][74][75][76][77][78][79][80][81].…”

Section: Discussionmentioning

confidence: 99%

Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study

Battista,

Gallo,

Martora

et al. 2024

JCM

View full text Add to dashboard Cite

Background: It is now recognized that psoriasis plays a key role in the development of several comorbidities, such as cardiovascular disease, and metabolic syndrome. Some authors have hypothesized that patients with psoriasis may have an increased risk of developing certain types of cancer. The efficacy and safety of biologic drugs are well-documented in clinical trials and in real-life studies. However, there is limited evidence on the safety of the use of biologic treatments in cancer patients with psoriasis, and the use of this therapeutic class in patients with a pre-existing or concomitant malignancy is still debated. Methods: We have conducted a retrospective observational study of a group of oncology patients with moderate-to-severe psoriasis treated with biologic therapy at the Dermatology Clinic of the University of Naples Federico II, during the period from 2016 to 2024. We included 20 adult patients; in 15 of them the diagnosis of neoplasm preceded the start of treatment biologic, while four of these patients had been diagnosed with cancer during the course of therapy biologics. Results: The most represented neoplasms in our population were breast carcinoma, prostate carcinoma, thyroid carcinoma, and chronic lymphatic leukemia. Anti-IL17 drugs were the most frequently prescribed (47.7%), followed by anti-IL23p19 (36.8%), anti-IL-12/23 (10.5%) and anti-TNF alpha (5.26%). All patients showed improvement of psoriasis after starting the therapy. Conclusions: Our experience supports the effectiveness and safety of biological therapy for psoriasis in patients with a history of cancer or recent onset neoplasia.

show abstract

Section: Discussionmentioning

confidence: 99%

Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study

Battista,

Gallo,

Martora

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…Its use in plaque psoriasis resulted in a 75% reduction in the psoriasis area severity index (PASI 75) [ 82 ]. A case study on patients with psoriasis and laryngeal cancer indicated the possible beneficial effect of ixekizumab on laryngeal cancer [ 83 ]. This claim is supported by research suggesting the increased apoptosis of LC cells when IL-17 is inhibited [ 84 ].…”

Section: Drugs Targeting Il-17 Axismentioning

confidence: 99%

Interleukin 17 and Its Involvement in Renal Cell Carcinoma

Jarocki

Karska

Kowalski

et al. 2022

JCM

View full text Add to dashboard Cite

Nowadays, molecular and immunological research is essential for the better understanding of tumor cells pathophysiology. The increasing number of neoplasms has been taken under ‘the molecular magnifying glass’ and ,therefore, it is possible to discover complex relationships between the cytophysiology and immune system action. An example could be renal cell carcinoma (RCC) which has deep interactions with immune mediators such as Interleukin 17 (IL-17)—an inflammatory cytokine reacting to tissue damage and external pathogens. RCC is one of the most fatal urological cancers because of its often late diagnosis and poor susceptibility to therapies. IL-17 and its relationship with tumors is extremely complex and constitutes a recent topic for numerous studies. What is worth highlighting is IL-17’s dual character in cancer development—it could be pro- as well as anti-tumorigenic. The aim of this review is to summarize the newest data considering multiple connections between IL-17 and RCC.

show abstract

Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease

Farina,

Tomelleri,

Boffini

et al. 2024

Rheumatol Int

View full text Add to dashboard Cite

Successful outcome of psoriasis in a laryngeal cancer patient treated with ixekizumab, a possible beneficial treatment for both pathologies

Cited by 6 publications

References 6 publications

Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study

Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study

Interleukin 17 and Its Involvement in Renal Cell Carcinoma

Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease

Contact Info

Product

Resources

About